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ABSTRACT 
Background  Patients with chronic obstructive pulmonary disease (COPD) can be classified into 
groups A/C or B/D based on symptom intensity. Different threshold values for symptom 
questionnaires can result in misclassification and, in turn, different treatment recommendations. 
The primary aim was to find the best fitting cut-points for Global initiative for chronic Obstructive 
Lung Disease (GOLD) symptom measures, with a modified Medical Research Council dyspnea 
grade of 2 or higher as point of reference. 
Methods  After a computerized search, data from 41 cohorts and whose authors agreed to 
provide data were pooled. COPD studies were eligible for analyses if they included, at least age, 
sex, postbronchodilator spirometry, modified Medical Research Council, and COPD Assessment 
Test (CAT) total scores. 
Main outcomes Receiver operating characteristic curves and the Youden index were used to 
determine the best calibration threshold for CAT, COPD Clinical Questionnaire, and St. Georges 
Respiratory Questionnaire total scores. Following, GOLD A/B/C/D frequencies were calculated 
based on current cut-points and the newly derived cut-points. 
Findings  A total of 18,577 patients with COPD [72.0% male; mean age: 66.3 years (standard 
deviation 9.6)] were analyzed. Most patients had a moderate or severe degree of airflow limitation 
(GOLD spirometric grade 1, 10.9%; grade 2, 46.6%; grade 3, 32.4%; and grade 4, 10.3%). The best 
calibration threshold for CAT total score was 18 points, for COPD Clinical Questionnaire total 
score 1.9 points, and for St. Georges Respiratory Questionnaire total score 46.0 points. 
Conclusions The application of these new cut-points would reclassify about one-third of the 
patients with COPD and, thus, would impact on individual disease management. Further validation 
in prospective studies of these new values are needed.  
INTRODUCTION 
The Global initiative for chronic Obstructive Lung Disease (GOLD) is a recent practice strategy 
on the diagnosis, prevention, and management of chronic obstructive pulmonary disease (COPD) 
(1). Patients with COPD are classified based on postbronchodilator spirometry into grade I (forced 
expiratory volume in the first second, FEV1 ≥80% predicted), grade II (FEV1 50% to <80% 
predicted), grade III (FEV1 30% to <50% predicted), or grade IV (FEV1 <30% predicted). 
Additionally, patients are classified in groups A to D for specific therapeutic recommendations 
based on the degree of symptoms (low vs high), and the history of exacerbations and 
hospitalizations. 
 
High symptoms are determined using various questionnaires: the modified Medical Research 
Council scale (mMRC, grade 2 or higher), the COPD Clinical Questionnaire (CCQ) total score (1 
point or higher), the COPD Assessment test (CAT) total score (10 points or higher), and the St. 
Georges Respiratory Questionnaire (SGRQ) total score (25 points or higher) (1). 
 
The choice of symptom questionnaire impacts the classification of patients with COPD in gold 
A/C OR B/D groups (2-5). mMRC only focusses on the impact of dyspnea, the most common 
symptom of patients with COPD. The other symptom questionnaires also take other aspects of 
health-related quality of life into consideration. Therefore, the CAT, CCQ, or SGRQ may be 
preferred over MMRC. However, mMRC is easy to obtain, and, it is the most frequently used in 
clinical practice and studies, and is suggested to be used to categorize patients into symptom 
severity groups for the purpose of treatment (1,6). 
 
Previous studies suggest that the current cut-points need proper validation (4,7-10). Indeed, the 
GOLD Scientific Committee recognized that a calibration of the current cut-points of the 
symptom measures is an important topic that needs to be addressed in the next major revision of 
the gold document (10). Then again, the former threshold values for mMRC, SGRQ, and CAT are 
still used in the GOLD 2017 strategy.1 Interestingly, the GOLD document indicates that 
multidimensional scores like CAT do not categorize patients into symptom severity groups for the 
purpose of treatment, suggesting a central role of mMRC for patient classification. Therefore, new 
classification schemes should be benchmarked against mMRC. 
 
The primary aim of this patient-level pooled analysis was to find best fitting cut-points for GOLD 
symptom measures, with a mMRC dyspnea grade of 2 or higher as the point of reference. 
Following, the impact of the newly derived cut-points of all questionnaires on the frequency 
distribution of the GOLD staging was studied. 
  
METHODS 
This is a pooled analysis of concurrent cohort studies assessing mMRC and multidimensional 
evaluation systems in COPD. To identify the original cohorts, we performed a computerized search 
in the database Medline/Pubmed for reports published from the first CAT publication (September 
2009) to June 2015 (11). D.S., S.H-W., or M.S. approached the corresponding authors to gather 
information about their readiness to partake and the availability of a minimum required set of 
individual data of patients with COPD, including age, sex, postbronchodilator FEV1, CAT total 
score, and mMRC dyspnea grade. All participants within their respective studies gave their 
informed written consent to participate in the original study, and each study was approved by their 
respective ethics committee. 
Measurements 
The individual demographics and clinical characteristics [sex, age (years), height (m), weight (kg), 
smoking status (current/former/never), pack years, use of long-term oxygen therapy (yes/no), 
FEV1 (liters), FEV1 (% predicted), FEV1/FVC (%), mMRC dyspnea grade, CAT total score 
(points), CCQ total score (points), SGRQ total score (points), and number of COPD exacerbations 
and/or hospitalizations in the last 12 months] were provided from each dataset. All data were 
pooled, and the dataset was cleaned. 
Statistics 
Mean (standard deviation), median (interquartile range), or proportions were calculated, whatever 
appropriate. Pearson product moment correlations between mMRC dyspnea grade, CAT total 
score, CCQ total score, and SGRQ total score were performed. A r-value of <±0.20 indicates no 
meaningful correlation; ±0.20 to ±0.34, weak; ±0.35 to ±0.50, moderate; and >±0.50, strong 
correlation (12). Postbronchodilator FEV1 was used to classify patients into spirometric grades 1-
4. Allocation to GOLD groups A-D was done using mMRC ≥2, CAT ≥10, CCQ ≥1, and SGRQ 
≥25 in combination with exacerbations history. In addition, patients were re-allocated (if 
applicable) based on the newly derived cut-points in combination with exacerbations history. 
 
Receiver operating characteristic (ROC) curves were used to reveal the cut-points for the GOLD 
symptom measures that discriminate best between the 2 clusters defined on mMRC dyspnea grade 
(2 or higher). ROC curve represented dependency between the sensitivity and specificity of the 
binary classification for different cut-points of the GOLD symptom measures. The cut-point, 
which satisfied the optimal criterion of the Youden index (13), was referred as the best calibration 
threshold. The optimal cut-points were calculated for CAT total score, CCQ total score, and SGRQ 
total score. A software environment R v 3.1.0 was used. The ROC function from the pROC 
package was used to visualize the ROC curves and calculate the best thresholds. 
 
Graphs were created using GraphPad Prism v 6 (GraphPad Software Inc. San Diego, CA). Statistics 
were performed using SPSS for Windows, v 20.0 (IBM Corp, Armonk, NY). A P value of ≤.01 
was interpreted as statistically significant, to obtain a greater statistical power than the usual P value 
of <.05. 
 
  
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure E1. Flow diagram of subject inclusion  
 
n=18    non-responding authors (21-38)        
 
Accessible data: 
n= 45 
Total number of patients 
with minimal required 
data: 18,577 
n=311 article not relevant 
n=17    no mMRC, CAT and/or exacerbation data 
Articles with required data: 
n= 63 
n= 1,569   FEV1/FVC (%) ≥70 
n= 2,053   FEV1% predicted <10 or ≥120 or missing 
n= 145      no mMRC dyspnea score 
n= 1,300   no CAT total score 
n= 229     age (years) < 40 year or missing 
n= 54        gender missing 
 
 
 
 
Suitable articles: 
n= 40 
n=4 overlap with other articles 
n=1    no measured FEV1 (% predicted) (5) 
Total number of datasets: 
n= 41 
n=1   Additional available datasets (COSYCONET) 
Total number of articles: 
n= 337 
Total number patients: 
23,927 
Table 1. General characteristics per resource article 
Values expressed as mean (SD), median (IQR) or number of patients (%). Abbreviations: BMI= body mass index; CAT= COPD Assessment Test; CCQ= Clinical 
COPD Questionnaire; FEV1= Forced Expiratory Volume in the first second; FVC= Forced Vital Capacity; GOLD= Global initiative for chronic Obstructive Lung Disease; 
LTOT= long-term oxygen therapy; mMRC= modified Medical Research Council dyspnoea scale; SGRQ= St. George’s Respiratory Questionnaire. a 8 missing; b 1 missing; c 7 
missing; d 190 missing; e 462 missing; f 522 missing; g 495 missing; h 11 missing; i 4missing; j 474missing; k 25missing; l 18 missing; m 159 missing; n  157 missing; o 2 missing; 
p 71  missing; q 6 missing; r 49 missing; s 151 missing; t 218 missing; u 151 missing; v 11 missing; w 2 missing; x 2 missing; y 12 missing. 
   
 Dataset resource 
Lead author Agusti  
(39) 
Billington  
(40) 
Boutou  
(41) 
De Torres 
(42) 
Casanova 
(43) 
Casanova 
(43) 
Chaplin 
(44) 
Dodd 
(45) 
Horita 
(46) 
Jehn 
(47) 
Jones 
(2) 
Karch  
(20) 
Journal and year Qual Life Res, 
2015 
COPD, 2015 BMJ Open Respir 
Res, 2014 
CHEST, 
2014 
Respir 
Res, 2014 
Chest, 
2014 
J Cardiopulm 
Rehabil Prev, 2015 
Thorax, 
2011 
Clin Respir 
J, 2013 
Environ Health, 
2013 
ERJ, 2013 Respir Med, 2016 
Country  Spain UK UK Spain 
 
UK UK Japan Germany Belgium, France, UK, 
Germany, Italy, the 
Netherlands and Spain  
Germany 
 
Cohort GSK   CHAIN     HEED COSYCONET 
n 110 61 703 785 166 196 74 34 1725 2258 
Gender (male), n (%) 104 (94.5) 29 (47.5) 348 (49.5) 658 (83.8) 89 (53.6) 114 (58.2) 60 (81.1) 22 (64.7) 1251 (72.5) 1379 (61.1) 
Age, years 70.3 (9.7) 71.2 (10.0) 67.3 (9.8) 67.8 (8.8) 70.8 (8.7) 69.2 (9.0) 72.3 (9.4) 63.5 (9.9) 64.9 (9.7) 65.1 (8.4) 
Current smoker, n (%) 28 (25.5) 32 (52.5) - 223 (28.4) - - 11 (14.9) 28 (82.4) 737 (42.7) 561 (24.8) 
Packyears 40.0 (24.6-54.3)a - - 55.9 (28.0)h - - 51.6 (30.4) 15.7 (12.1) 38.4 (19.2)p 41.2 (22.0-63.0)v 
BMI, kg/m2 - 26.1 (22.3-29.9) 26.0 (22.4 -30.0)d 27.8 (24.8-31.0)i 27.7 (7.0)k 27.6 (6.6)l 21.2 (3.0) 26.5 (19.9-29.8) 27.0 (4.9)q 26.2 (23.2-29.4)w 
FEV
1 
(% pred.) 63.6 (20.0) 65.4 (15.8) 49.2 (18.8) 59.3 (20.2) 56.2 (24.4) 51.2 (19.4) 43.2 (12.7) 46.2 (13.4) 56.4 (19.7) 52.5 (18.5) 
FEV
1
/FVC (%) 54.0 (11.2)b 53.0 (10.2) 43.9 (14.5)e 51.9 (11.3) - - 59.7 (7.7) 42.3 (13.2)o 56.2 (10.6)r 51.3 (11.0) 
LTOT, n (%) - - - 69 (22.3)j - - 16 (21.6) 8 (23.5) - 436 (19.3) 
GOLD stage, n (%)  -   I 
                                    -  II 
                                    -  III 
                                    -  IV 
24 (21.8) 
57 (51.8) 
24 (21.8) 
5 (4.5) 
12 (19.7) 
39 (63.9) 
9 (14.8) 
1 (1.6) 
45 (6.4) 
289 (41.1) 
246 (35.0) 
123 (17.5) 
134 (17.1) 
377 (48.0) 
231 (29.4) 
43 (5.5) 
35 (21.1) 
55 (33.1) 
50 (30.1) 
26 (15.7) 
16 (8.2) 
86 (43.9) 
65 (33.2) 
29 (14.8) 
0 (0.0) 
20 (27.0) 
42 (56.8) 
12 (16.2) 
0 (0.0) 
14 (41.2) 
15 (44.1) 
5 (14.7) 
216 (12.5) 
827 (47.9) 
540 (31.3) 
142 (8.2) 
202 (8.9) 
956 (42.3) 
856 (37.9) 
244 (10.8) 
Exacerbations previous  
12 months ≥2, n (%) 
9 (8.2) 41 (67.2) - 98 (12.5) - - - 11 (32.4) 451 (29.9)s 633 (28.0) 
Hospitalizations previous  
12 months ≥1, n (%) 
6 (5.5) - - 89 (11.3) - - - 20 (58.8) 155 (10.3)t 453 (20.1)x 
mMRC dyspnea grade  
≥2, n (%) 
49 (44.5) 41 (67.2) 576 (81.9) 358 (45.6) 131 (78.9) 148 (75.5) 35 (47.3) 16 (47.1) 751 (43.5) 1090 (48.3) 
CAT total score, points 16.3 (8.2) 14.8 (6.8) 21.2 (7.5) 12.1 (7.6) 21.8 (7.6) 20.2 (7.5) 11.1 (7.9) 19.1 (5.7) 17.7 (8.4) 18.1 (7.4) 
CCQ total score, points - - 3.1 (1.2)f 1.6 (1.1) - 2.9 (1.2)m - - - - 
SGRQ total score, points 44.5 (24.1)c - 47.3 (16.4)g - - 45.7 (19.1)n - - 44.7 (19.4)u 43.6 (19.9)y 
Values expressed as mean (SD), median (IQR) or number of patients (%). Abbreviations: BMI= body mass index; CAT= COPD Assessment Test; CCQ= Clinical COPD 
Questionnaire; FEV1= Forced Expiratory Volume in the first second; FVC= Forced Vital Capacity; GOLD= Global initiative for chronic Obstructive Lung Disease; LTOT= 
long-term oxygen therapy; mMRC= modified Medical Research Council dyspnoea scale; SGRQ= St. George’s Respiratory Questionnaire. a 125 missing; b 8 missing; c 3 
missing; d 7 missing; e 1 missing; f 3 missing; g 6 missing; h 125 missing; i 14 missing; j 5 missing; k 23 missing; l 21 missing. 
  
Dataset resource 
Author Kelly 
(48) 
Kim 
(49) 
Kon 
(50) 
Kwon 
(51) 
Lee 
(52) 
Ladeira 
(53) 
Lopez-Campos 
(54) 
Manca 
(55) 
Maricic 
(56) 
Mendoza 
(57) 
Mihaltan 
(58) 
Journal and year 
published 
Respiration, 
2012 
Pulm Med, 
2013 
Thorax, 2014 CHEST, 2013 Respir Med, 2014 Rev Port Pneumol, 
2015 
Int J COPD, 
2015 
COPD, 2014 Coll Antropol, 
2013 
Eur Respir J, 
2015 
Pneumologia, 
2015 
Country  UK South Korea the UK Indonesia, Korea, 
Vietnam and Hong 
Kong 
Australia, China, 
Korea and Taiwan 
Portugal Spain Spain Croatia Chile Romania 
Cohort  - - GSK GSK  On-Sint     
n 219 238 260 303 321 82 499 92 33 101 1082 
Gender (male), n (%) 139 (63.5) 192 (80.7) 151 (58.1) 296 (97.7) 286 (89.1) 64 (78.0) 407 (81.6) 67 (72.8) 25 (75.8) 62 (61.4) 801 (74.0) 
Age, years 64.0 (9.6) 67.8 (9.4) 71.0 (8.8) 69.0 (9.4) 69.7 (8.8) 70.2 (9.5) 67.1 (9.3) 66.1 (10.8) 62.6 (7.9) 68.8 (8.5) 63.1 (10.1) 
Current smoker, n (%) 28 (12.8) 51 (21.4) 31 (11.9) 53 (17.5) 62 (19.3) 17 (20.7) 115 (23.0)f 4 (4.3) 12 (36.4)l - 569 (52.6) 
Packyears 41.7 (23.2)a 27.9 (26.2) 41.1 (29.5) 30.0 (20.0-50.0) 40.0 (25.0-60.0) 41.5 (20.0-75.0) 38.3 (20.6) 33.0 (15.5-60.0) 41.6 (35.2) 40.5 (20.6) - 
BMI, kg/m2 25.2 (5.4)b 22.9 (3.2)c 27.0 (23.7-31.0) 20.8 (3.6) 23.4 (4.1) 26.2 (5.0) 27.7 (4.3)g 26.2 (4.7) 24.5 (3.5) 26.9 (4.5) - 
FEV
1 
(% pred.) 40.4 (17.9) 72.4 (23.7) 50.1 (20.6) 49.9 (18.0) 50.6 (19.3) 44.8 (16.3) 58.7 (18.4) 48.6 (17.2) 67.5 (16.9) 66.1 (19.5) 56.6 (17.8) 
FEV
1
/FVC (%) 36.9 (12.7) 54.5 (11.8) 50.4 (14.3) 50.0 (9.8) 46.5 (12.1) 67.0 (11.4) 54.6 (10.8)h 47.3 (11.6) 57.3 (7.9) 55.0 (9.5) - 
LTOT, n (%) 32 (14.6) - 12 (4.6) - - 47 (57.3) 69 (14.2)i 7 (7.6) - 3 (3.0) - 
GOLD stage, n (%)  -   I 
                                    -  II 
                                    -  III 
                                    -  IV 
8 (3.7) 
45 (20.5) 
96 (43.8) 
70 (32.0) 
99 (41.6) 
92 (38.7) 
38 (16.0) 
9 (3.8) 
26 (10.0) 
96 (36.9) 
84 (32.3) 
54 (20.8) 
18 (5.9) 
131 (43.2) 
121 (39.9) 
33 (10.9) 
25 (7.8) 
121 (37.7) 
137 (42.7) 
38 (11.8) 
2 (2.4) 
22 (26.8) 
48 (58.5) 
10 (12.2) 
55 (11.0) 
304 (60.9) 
112 (22.4) 
28 (5.6) 
5 (5.4) 
32 (34.8) 
45 (48.9) 
10 (10.9) 
6 (18.2) 
24 (72.7) 
2 (6.1) 
1 (3.0) 
28 (27.7) 
52 (51.5) 
18 (17.8) 
3 (3.0) 
119 (11.0) 
560 (51.8) 
336 (31.1) 
67 (6.2) 
Exacerbations previous  
12 months ≥2, n (%) 
132 (60.3) 126 (52.9) 117 (45.0) 95 (32.1)d 153 (47.7) 26 (31.7) 309 (62.6)j 29 (31.5) - - 470 (43.4) 
Hospitalizations previous  
12 months ≥1, n (%) 
- - - - - 25 (30.5) 161 (33.8)k 15 (16.3) - - - 
mMRC dyspnea grade  
≥2, n (%) 
183 (83.6) 93 (39.1) 185 (71.2) 169 (55.8) 153 (47.7) 54 (65.9) 247 (49.5) 51 (55.4) 6 (18.2) 49 (48.5) 665 (61.5) 
CAT total score, points 23.1 (8.1) 16.0 (9.3) 20.7 (7.9) 17.8 (8.1) 14.8 (8.0) 17.3 (8.2) 18.4 (7.6) 12.8 (8.1) 14.6 (7.7) 16.0 (8.2) 17.8 (7.9) 
CCQ total score, points - - 2.8 (1.2) - - - - - - - - 
SGRQ total score, points - - 49.3 (16.4) 45.4 (17.8)e - - - - - 42.8 (18.4) - 
Values expressed as mean (SD), median (IQR) or number of patients (%). Abbreviations: BMI= body mass index; CAT= COPD Assessment Test; CCQ= Clinical COPD 
Questionnaire; DSP= Disease Specific Programme; FEV1= Forced Expiratory Volume in the first second; FVC= Forced Vital Capacity; GOLD= Global initiative for chronic 
Obstructive Lung Disease; LTOT= long-term oxygen therapy; mMRC= modified Medical Research Council dyspnoea scale; SGRQ= St. George’s Respiratory Questionnaire. 
a 145 missing; b 717 missing; c 28 missing; d 2 missing; e 153 missing; f 10 missing; g 35 missing; h 2 missing; i 1 missing; j 29 missing; k 98 missing; l 98 missing; m 1 missing; n 
57 missing; o 319 missing; p 3 missing; q 62 missing; r 37 missing; s 4 missing; t 1 missing; u 2 missing.  
Dataset resource 
Author Miravitlles 
(59) 
Miravitlles 
(60) 
Minami 
(61) 
Nakken 
(62) 
Nishijima 
(63) 
Novotna 
(64) 
Pothirat 
(65) 
Pothirat 
(66) 
Price 
(67) 
Raghavan 
(68) 
Journal and year 
published 
IJTLD, 2015 Respir Med, 
 2014 
Multidiscip 
Respir Med, 2014 
BMJ Open, 
2014 
Int J Chron 
Obstruct Pulmon 
Dis, 2015 
IJCOPD, 2014 BMC Pulm Med, 
2014 
Int J Chron 
Obstruct Pulmon 
Dis, 2015 
Int J COPD, 2014 COPD, 2012 
Country  Spain Spain Japan The 
Netherlands 
Japan The Czech republic Thailand Thailand US, France,  Spain, 
Germany, Italy, UK 
Canada 
Cohort INSEPOC study     Czech Multicentre 
Research Database of 
COPD (CMRD) 
  Adelphi Respiratory 
DSP 
COLD 
n 2721 696 50 193 16 514 97 153 1070 111 
Gender (male), n (%) 2251 (82.7) 585 (84.1) 47 (94.0) 101 (52.3) 15 (93.8) 374 (72.8) 80 (82.5) 89 (58.2) 734 (68.6) 63 (56.8) 
Age, years 66.9 (9.7) 68.7 (9.3) 71.0 (8.9) 66.0 (8.7) 73.5 (6.6) 67.3 (8.1) 70.7 (8.2) 71.5 (8.5) 64.6 (10.4) 64.3 (10.6) 
Current smoker, n (%) 1959 (72.0)a 156 (22.4)f 11 (22.0)  32 (16.6) 2 (12.5) 93 (18.1) 5 (5.2) - 338 (31.6) 21 (18.9) 
Packyears 36.0 (24.0-50.0)b 43.2 (21.6) g 63.5 (32.2) 37.8 (28.3-51.4) 37.5 (24.6)m 38.0 (25.0-48.0)n 34.0 (19.0-59.5) - 32.0 (20.0-48.0)q 19.6 (22.6)u 
BMI, kg/m2 27.7 (4.3)c 26.8 (24.7-30.0)h 22.9 (3.8) 26.3 (5.3) 20.6 (2.4) 27.2 (5.9) 20.9 (3.5) 20.2 (3.9) 26.4 (23.4-29.4)r 27.2 (24.3-30.8) 
FEV
1 
(% pred.) 52.6 (18.9) 53.2 (19.6) 51.5 (18.9) 47.3 (17.7) 54.8 (18.5) 43.3 (11.2) 56.4 (21.0) 47.8 (17.6) 60.5 (16.0) 86.7 (15.8) 
FEV
1
/FVC (%) 53.4 (11.1)d 53.1 (12.1) i 59.3 (9.5) 40.3 (12.7) 59.6 (9.6) 50.5 (10.7) 50.8 (12.1) 51.9 (10.3) - 65.0 (60.0-67.6) 
LTOT, n (%) 302 (11.8)e 163 (24.4)j 0 (0.0) 53 (27.5) 0 (0.0) 78 (15.2) - - 143 (13.4) 0 (0.0) 
GOLD stage, n (%)  -   I 
                                    -  II 
                                    -  III 
                                    -  IV 
232 (8.5) 
1202 (44.2) 
984 (36.2) 
303 (11.1) 
46 (6.6) 
347 (49.9) 
229 (32.9) 
74 (10.6) 
4 (8.0) 
22 (44.0) 
17 (34.0) 
7 (14.0) 
0 (0.0) 
93 (48.2) 
62 (32.1) 
38 (19.7) 
0 (0.0) 
10 (62.5) 
3 (18.8) 
3 (18.8) 
0 (0.0) 
168 (32.7) 
278 (54.1) 
68 (13.2) 
14 (14.4) 
42 (43.3) 
27 (27.8) 
14 (14.4) 
10 (6.5) 
58 (37.9) 
61 (39.9) 
24 (15.7) 
112 (10.5) 
711 (66.4) 
203 (19.0) 
44 (4.1) 
77 (69.4) 
32 (28.8) 
2 (1.8) 
0 (0.0) 
Exacerbations previous  
12 months ≥2, n (%) 
1402 (51.5) 420 (70.2)k 7 (14.0) 104 (53.9) 2 (12.5) 162 (31.5) 13 (13.4) - 356 (33.4)s - 
Hospitalizations previous  
12 months ≥1, n (%) 
341 (12.5) 162 (27.1)l 6 (12.0) 81 (42.0) 2 (12.5) 141 (27.4) - - 150 (14.0)t - 
mMRC dyspnea grade  
≥2, n (%) 
1526 (56.1) 449 (64.5) 34 (68.0) 150 (77.7) 7 (43.8) 391 (76.1) 39 (40.2) 96 (62.7) 377 (35.2) 8 (7.2) 
CAT total score, points 19.2 (8.2) 21.3 (8.2) 11.6 (7.1) 21.2 (7.1) 16.0 (10.3) 16.6 (7.8) 12.3 (7.3) 12.4 (7.3) 20.6 (8.5) 8.4 (6.3) 
CCQ total score, points - - - - - - - - - - 
SGRQ total score, points - - - - - 48.0 (18.5)o 38.3 (20.7) 42.1 (21.0)p - - 
 Values expressed as mean (SD), median (IQR) or number of patients (%). Abbreviations: BMI= body mass index; CAT= COPD Assessment Test; CCQ= Clinical COPD 
Questionnaire; DSP= Disease Specific Programme; FEV1= Forced Expiratory Volume in the first second; FVC= Forced Vital Capacity; GOLD= Global initiative for chronic 
Obstructive Lung Disease; LTOT= long-term oxygen therapy; mMRC= modified Medical Research Council dyspnoea scale; SGRQ= St. George’s Respiratory Questionnaire. 
a 8 missing; b 13 missing; c 113 missing; d 12 missing; e 188 missing; f 44 missing; g 1 missing; h 22 missing; i 3 missing; j 1 missing; k 11 missing; l 1 missing; m 16 missing; n 3 
missing; o 3 missing. 
 
 Dataset resource 
Author Ringbaek 
(69) 
Da Silva 
(18) 
Da Silva  
(19) 
Sigari 
(70) 
Tsiligianni 
(71) 
Tulek 
(72) 
Jones 
(16) 
Vestbo 
(17) 
Wilke 
(3) 
Xie 
(73) 
Yoshikawa 
(74) 
Zogg 
(75) 
Journal and year 
published 
COPD, 
2012 
Qual Life 
Res, 2014 
J Bras Pneumol, 
2013 
Rheumatol Int, 
2015 
BMC Pulm Med, 
2012 
Respirology, 
2014 
Respir Med, 
2014 
Respir Med, 
2014 
J COPD F, 2014 Chin Med J, 2014 Respirology, 
2014 
BMC Res 
Notes, 2014 
Country  Denmark Brazil Iran Greece Turkey US, France, Germany, Italy, 
Spain, UK 
The Netherlands Shanghai Japan Switzerland 
Cohort      Adelphi Respiratory DSP - -   
n 118 50 78 90 119 1491 698 844 58 68 
Gender (male), n (%) 47 (39.8) 24 (48.0) 45 (57.7) 82 (91.1) 116 (97.5) 1019 (68.3) 391 (56.0) 659 (78.1) 56 (96.6) 41 (60.3) 
Age, years 68.2 (9.6) 66.2 (8.5) 60.5 (8.0) 67.4 (8.7) 59.5 (9.3) 65.1 (10.2) 64.8 (8.9) 68.0 (9.1) 72.1 (9.2) 67.2 (10.4) 
Current smoker, n (%) 22 (18.6)a - 27 (34.6) 70 (77.8) - 487 (32.9)d 166 (23.8)g 623 (73.8) 20 (34.5) 32 (47.1) 
Packyears 41.7 (22.6)b - 29.1 (34.7) 60.0 (40.0-84.3) 38.3 (10.2) 30.0 (20.0-45.0)e 40.0 (28.0-50.0)h 22.5 (15.0-31.0)k 60.0 (45.8-80.0) 45.8 (32.5)n 
BMI, kg/m2 24.8 (5.8) 25.9 (5.1) - 27.8 (5.1) 27.6 (5.3) 26.5 (23.4-29.4)f 26.1 (5.4) 22.9 (3.0) 21.0 (3.5) 25.1 (21.1-28.9) 
FEV
1 
(% pred.) 33.7 (9.3) 44.1 (13.8) 48.7 (17.4) 58.2 (18.8) 59.2 (20.0) 62.6 (17.1) 54.7 (22.3) 48.0 (17.2) 50.8 (19.7) 64.3 (21.9) 
FEV
1
/FVC (%) - 48.7 (10.8) 56.1 (8.9) 55.7 (10.7) - - 42.3 (14.0) 54.7 (10.1) 43.5 (12.7)l 50.1 (12.4) 
LTOT, n (%) 4 (3.4) - 5 (6.4) 1 (1.1) - 117 (7.8) 136 (19.5) 202 (23.9) 10 (17.2) 2 (3.1)o 
GOLD stage, n (%)  -   I 
                                    -  II 
                                    -  III 
                                    -  IV 
0 (0.0) 
6 (5.1) 
70 (59.3) 
42 (35.6) 
0 (0.0) 
18 (36.0) 
25 (50.0) 
7 (14.0) 
7 (9.0) 
28 (35.9) 
35 (44.9) 
8 (10.3) 
15 (16.7) 
46 (51.1) 
21 (23.3) 
8 (8.9) 
17 (14.3) 
64 (53.8) 
30 (25.2) 
8 (6.7) 
256 (17.2) 
936 (62.8) 
241 (16.2) 
58 (3.9) 
115 (16.5) 
259 (37.1) 
220 (31.5) 
104 (14.9) 
31 (3.7) 
310 (36.7) 
366 (43.4) 
137 (16.2) 
5 (8.6) 
22 (37.9) 
25 (43.1) 
6 (10.3) 
13 (19.1) 
38 (55.9) 
12 (17.6) 
5 (7.4) 
Exacerbations previous  
12 months ≥2, n (%) 
- - 31 (39.7) 2 (2.2) 48 (40.3) 465 (31.2) 330 (47.3) 386 (45.7) 7 (12.1) 8 (11.8) 
Hospitalizations previous  
12 months ≥1, n (%) 
- - 39 (50.0) 5 (5.6) 28 (23.5) 196 (13.1) 239 (34.3) 218 (25.8) 5 (8.6) - 
mMRC dyspnea grade  
≥2, n (%) 
118 (100.0) 25 (50.0) 70 (89.7) 22 (24.4) 64 (53.8) 758 (50.8) 490 (70.3) 534 (63.3) 36 (62.1) 28 (41.2) 
CAT total score, points 18.3 (6.6) 20.8 (9.9) 25.1 (8.7) 12.9 (7.5) 13.1 (8.1) 21.0 (8.8) 20.0 (7.4) 18.3 (7.9) 15.2 (7.7) 13.3 (7.0) 
CCQ total score, points - - - 1.6 (1.0) - - 2.3 (1.1)i - - - 
SGRQ total score, points 42.8 (7.0)c 44.9 (20.4) - 36.8 (18.3) - - 54.0 (22.0)j - 42.0 (15.9)m - 
RESULTS 
Overall, 337 reports were identified, of which 63 were eligible (Figure 1). Forty-five author groups 
were able and willing to participate. Finally, 41 datasets were included in the patient level pooled 
analysis. At the time of inclusion, 3 articles were published with the dataset of the COPD History 
Assessment In SpaiN (CHAIN) cohort (14), 3 articles used the Adelphi Respiratory Disease 
Specific Program dataset (one of which is from another subcohort (15) than the other 2 articles 
(16,17)), 1 author group published 2 articles with the same dataset (18,19), and 1 dataset did not 
have recently measured FEV1 (% predicted) (5). In addition, the COPD and SYstemic 
consequences-COmorbidities NETwork (COSYCONET) steering committee approved to share 
their cohort baseline data (20). Table 1 provides all details per study. 
 
Demographic and clinical characteristics of 18,577 patients with COPD are presented in Table 2. 
Most patients had a moderate or severe degree of airflow limitation. Spirometric grade 2 was the 
most prevalent (46%). Using the GOLD 2017 cut-points, the majority of patients were classified 
in the high-symptom B/D groups: mMRC, 55.3%; CAT, 83.6%; CCQ, 78.8%; and SGRQ 83.0%. 
 
The degree of airflow limitation correlated weakly-to-moderately with the mMRC dyspnea grade 
(r=-0.40, P < .001), CAT total score (r=-0.26, P < .001), CCQ total score (r=-0.37, P < .001), and 
SGRQ total score (r=-0.36, P < .001; Figure 2). Moreover, the symptom measures interrelated 
strongly, with the Pearson product-moment correlation coefficients ranging from 0.540 to 0.799 
(all P < .001; Figure 3). 
New Cut-Points 
Figure 4 shows the newly proposed cut-points. A CAT cut-point of 18 points, a CCQ cut-point of 
1.9 points, and a SGRQ cut-point of 46.0 points reached the highest sensitivity and specificity vs 
the mMRC dyspnea grade of 2 or higher as point of reference. 
Frequency Distribution 
GOLD A/B/C/D frequencies based on current cut-points and the newly derived cut points are 
shown in Figure 5. Compared with the existing CAT cut-point (≥10 points), the new cut-point (≥18 
points) re-classified 30.2% of the GOLD B/D patients into GOLD A/C. Compared with the 
existing CCQ cut-point (≥1 point), the new cut-point (≥1.9 points) re-classified 23.9% of the 
GOLD B/D patients into GOLD A/C. Compared to the existing SGRQ cut-point (≥25 points), 
the new cut-point (≥46 points) re-classified 34.3% of the GOLD B/D patients into GOLD A/C. 
 
  
Table 2. General characteristics of total population  
Values expressed as mean (SD), median (IQR) or number of patients (%). Abbreviations: BMI= body mass index; 
CAT= COPD Assessment Test; CCQ= Clinical COPD Questionnaire; FEV1= Forced Expiratory Volume in the first 
second; FVC= Forced Vital Capacity; GOLD= Global initiative for chronic Obstructive Lung Disease; LTOT= long-
term oxygen therapy; mMRC= modified Medical Research Council dyspnoea scale; SGRQ= St. George’s Respiratory 
Questionnaire 
  
Variables n=  
Gender (male), n (%) 18,577 13,370 (72·0) 
Age, years 
-    40-50 years, n (%) 
-    51-60 years, n (%) 
-    61-70 years, n (%) 
-    71-80 years, n (%) 
-    >80 years, n (%) 
18,577 66.3 (9.6) 
1,122 (6.0) 
3,978 (21.4) 
6,985 (37.6) 
5,380 (29.0) 
1,112 (6.0) 
Current smoker, n (%) 16,888 6,626 (35.7) 
Pack years 14,234 38.0 (23.0-52.5) 
BMI, kg/m2 16,934 26.5 (5.2) 
FEV1 (% pred.) 18,577 54.6 (19.5) 
FEV1/FVC (%) 13,692 51.8 (12.1) 
LTOT, n (%) 12,547 1,903 (10.2) 
GOLD spirometric grade, n (%)      -      1 
                                                        -      2 
                                                        -      3 
                                                        -      4 
18,577 2,029 (10.9) 
8,611 (46.4) 
6,026 (32.4) 
1,911 (10.3) 
Exacerbations previous 12 months ≥2, n (%) 16,607 6,443 (38.8) 
Hospitalizations previous 12 months ≥1, n (%) 13,881  2,537 (18.3) 
mMRC grade, n (%)    -     0 
                                    -     1 
                                    -     2 
                                    -     3 
                                    -     4 
18,577 2,183 (11.8) 
6,122 (33.0) 
5,474 (29.5) 
3,598 (19.4) 
1,200 (6.5) 
mMRC dyspnea grade ≥2, n (%) 18,577 10,272 (55.3) 
CAT total score, points 18,577  18.4 (8.4) 
Percentage subjects with value ≥10, n (%)  15,535 (83.6) 
CCQ total score, points 2,047 2.1 (1.3) 
Percentage subjects with value ≥1, n (%)  1,614 (78.8) 
SGRQ total score, points 6,159 45.4 (20.0) 
Percentage subjects with value ≥25, n (%)  5,114 (83.0) 
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Figure 4. Receiver operating characteristic (ROC) curves showing best pairwise classification thresholds. 
CAT= COPD Assessment Test; CCQ= Clinical COPD Questionnaire; SGRQ= St. George’s Respiratory 
Questionnaire. 
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DISCUSSION 
Healthcare professionals should be aware of the fact that the choice of symptom measure 
influences classification, and, in turn, also specific treatment recommendation in patients with 
COPD. Using mMRC ≥2 points as a reference, a CAT cut-point of 18 points, CCQ cutpoint of 
1.9 points, and SGRQ cut-point of 46.0 points reached the highest agreement. Implementation of 
these newly derived cut-points will influence the management of individual patients and the design 
and interpretation of clinical studies. 
Recommendations 
As the newly derived cut-points reached the highest sensitivity and specificity with the mMRC 
dyspnea grade of 2 or higher, guidelines committees may need to consider the use of a mMRC 
dyspnea grade 2 or higher, a CAT total score of 18 points or higher, a CCQ total score of 1.9 points 
or higher, or a total SGRQ score of 46.0 points or higher to classify patients with COPD as 
symptomatic (ie, GOLD B or D; 
Figure 6). This recommendation is supported by the fact that a CAT total score ≥10 points already 
occurs in 50% of current or former smokers without having any airway obstruction (76). The newly 
derived cut-points enable healthcare professionals to classify the largest proportion of patients into 
the same GOLD quadrant regardless of their choice of symptom measure.  
Clinical Consequences 
Future studies are needed to assess the effectiveness of bronchodilators in COPD patients with 
and without symptoms, using the newly derived cut-points. For example, GOLD A patients are 
advised to use short-acting bronchodilators, whereas GOLD B patients are advised to use long-
acting bronchodilators (1). Therefore, the new cutpoints may reduce the prescription of long-acting 
bronchodilators in patients who are currently GOLD B, and will become GOLD A by applying 
the new cut-points. Obviously, the question arises what to do with COPD patients with a mMRC 
grade below 2 and a CAT score between 10 (current cut-point) and 18 points (newly derived cut 
point)? This combination of scores suggests that these patients suffer from other symptoms than 
dyspnea, which can most probably not be treated satisfactorily with the current pulmonary drug 
therapy. 
 
The newly proposed cut-points may also affect recruitment criteria for upcoming trial designs. 
Indeed, studies that previously applied the current cut-points, will have an overrepresentation of 
GOLD B or D patients. Sillen et al (77) showed that there is a lot of heterogeneity in GOLD group 
D, when applying the existing cutpoints. In turn, adjusting cut-points of the symptom measures to 
the newly derived cut-points will increase baseline homogeneity of patient populations within 
observational COPD studies and intervention trials. 
 
The current analysis confirms that the degree of airflow limitation only moderately correlates with 
the symptom measures. So, the degree of symptom burden cannot accurately be derived from 
spirometry. Therefore, healthcare professionals need to regularly assess symptoms in patients with 
COPD. Indeed, a change in symptom scores may even have a prognostic value in patients with 
COPD (78). 
  
  
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Suggested GOLD ABCD diagram, using the new cut-points to assess symptoms. CAT= COPD 
Assessment Test; CCQ= Clinical COPD Questionnaire; GOLD= Global initiative for chronic Obstructive 
Lung Disease; mMRC= modified Medical Research Council dyspnoea scale; SGRQ= St. George’s 
Respiratory Questionnaire.  
Strengths and Limitations 
The pooled, multicenter, multinational, patient level dataset with a large number of patients and 
global coverage is a major strength. Indeed, this resulted in a heterogeneous sample of patients 
with COPD, also including a high number of patients with a low mMRC dyspnea grade (grade 0: 
2183 patients; grade 1: 6122 patients), patients with a mild degree of airflow limitation (spirometric 
grade 1: 2029 patients), and 1,122 patients younger than 50 years of age. Moreover, patients were 
recruited from various care settings (ie, primary care, general population, hospital outpatients). This 
makes the results more generalizable. 
 
A limitation of the current study is that the largest proportion of patients was male (72.0%). 
Although this seems to over-represent the male sex, it is probably a reliable representation of the 
current COPD population in the participating cohorts (79). Less data were available for the CCQ 
total score (2047 patients) and SGRQ total score (6159 patients). Furthermore, the definition of 
COPD, current, former or never smoker and the definition of exacerbations and hospitalizations 
could differ between studies. Finally, the mMRC dyspnea grade solely captures symptoms of 
dyspnea, which may, together with spirometry and history of exacerbations/hospitalizations, be a 
suitable guidance for treatment recommendations. Nevertheless, mMRC dyspnea scale may be too 
limited to truly understand the impact of COPD. Indeed, symptoms like fatigue, pain and insomnia, 
may also occur in patients with COPD (80). Therefore, CAT, CCQ, or SGRQ may be preferred to 
more broadly characterize the daily symptoms of patients with COPD. Obviously, when CAT, 
CCQ, and SGRQ are applied for the binary classification of high vs low symptoms, there will still 
be discrepancy between these symptom measures. So, the GOLD Scientific Committee may want 
to consider the choice of 1 symptom measure or applying the worst scoring questionnaire to classify 
patients into groups A/C or B/D. 
CONCLUSIONS 
To objectively define a symptom burden score equivalent to a mMRC dyspnea grade of 2 or higher, 
a CAT total score of ≥18 points, a CCQ total score of ≥1.9 points, or a SGRQ total score of ≥46 
points should be used. Following this grading, about one-third of the patients in GOLD groups 
B/D are re-classified to GOLD groups A/C. This implies that guidelines committees may consider 
adapting our evidence-based cut-points of symptom measures. 
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